PROCEPT BioRobotics Corporation

PROCEPT BioRobotics Corporation is a surgical robotics company dedicated to advancing patient care through transformative solutions in urology. The company's mission is to revolutionize benign prostatic hyperplasia (BPH) treatment globally by partnering with urologists to deliver best-in-class robotic solutions that positively impact patients and drive value. Headquartered in San Jose, California, PROCEPT BioRobotics focuses on developing innovative technologies for men's health.

The company develops, manufactures, and sells the AquaBeam Robotic System and the HYDROS Robotic System. These image-guided, surgical robotic systems are utilized in minimally invasive urologic surgery, primarily for the treatment of benign prostatic hyperplasia (BPH) using Aquablation therapy. The HYDROS Robotic System represents the next-generation, AI-powered platform for delivering Aquablation therapy, which combines real-time imaging, personalized treatment planning, automated robotics, and a heat-free waterjet for targeted prostate tissue removal.

Larry L. Wood assumed the role of President and CEO on September 2, 2025, succeeding Dr. Reza Zadno. The company has recently expanded its global reach with the international launch of the HYDROS Robotic System in March 2026, following its FDA clearance in August 2024. PROCEPT BioRobotics reported strong financial performance in Q1 2026, with a 20% year-over-year revenue increase. The European Association of Urology guidelines also upgraded Aquablation therapy to a strong surgical recommendation for BPH in March 2026, reinforcing the company's market positioning as a leader in robotic solutions for urology.

Latest updates

Procept BioRobotics Revenue Growth Masks Rising Expenses, Guidance Holds

Event summary

  • Procept BioRobotics reported Q1 2026 revenue of $83.1 million, a 20% increase YoY.
  • U.S. procedures grew by 30% YoY to approximately 12,200, with handpiece sales normalizing to 95% of procedures.
  • Operating expenses increased to $86.6 million, driven by investments in commercial expansion, R&D, and a prostate cancer trial.
  • The company’s net loss widened to $31.6 million in Q1 2026, compared to $24.7 million in the prior year period.
  • Procept received FDA clearance for its second-generation FirstAssist AI™ software.

The big picture

Procept BioRobotics is navigating a period of accelerated growth in the surgical robotics market, but faces challenges in balancing expansion with profitability. The company's focus on operational excellence and commercial discipline, while showing early signs of impact, needs to translate into sustained cost control to justify its valuation. The FDA clearance of FirstAssist AI represents a strategic opportunity to differentiate its platform, but its success hinges on surgeon adoption and demonstrable clinical benefits.

What we're watching

Cost Control
Whether Procept can effectively manage operating expenses, particularly R&D and commercial expansion costs, to improve profitability remains a key risk given the widening net loss.
International Growth
The sustainability of international revenue growth, currently at 25%, will depend on Procept’s ability to navigate varying regulatory landscapes and competitive pressures in new markets.
AI Adoption
The pace at which surgeons adopt and integrate the new FirstAssist AI software into their workflows will determine the extent of its impact on procedure efficiency and overall revenue generation.
CID: 3181